title: [Questionnaire on venous thromboembolism prevention by low molecular weight heparin in medical environment].
abstract: OBJECTIVE
  The aim of this prospective study was to observe the prescription of low-molecular weight heparin (LMWH) for the prophylaxis of venous thromboembolic disease in medical patients.
  
  
  METHODS
  We included all the patients on LMWH prophylaxis in 5 medical departments of Sainte-Marguerite Hospital in Marseille. The study described the reasons for this prophylaxis, the thrombotic risk, the follow-up quality and the side-effects.
  
  
  RESULTS
  During four months, 189 (14.3%) of 1317 medical patients have received a prophylaxis with LMWH; sixty one per cent of them were older than 70 years. Thrombotic risk as measured with Thilly's score was low in 50 patients (26%), moderate in 81 patients (43%), high in 58 patients (31%). Platelet count follow-up was optimal in 88 patients (47%). A decrease of platelet count over 30%, reaching less than 100 G/l, was recorded in 4 patients. A venous thrombosis was diagnosed clinically in one patient. Two patients had an overt severe bleeding. A serious hidden bleeding was suspected in 11 patients.
  
  
  CONCLUSIONS
  LMWH were frequently prescribed for the prophylaxis of venous thromboembolic disease in medical patients. Most of these patients were over 70 years of age. Platelet count follow-up was in accordance with guidelines in less than half of the patients. Bleedings were not rare on this treatment. The present work suggests that a precise thrombotic risk assessment is needed before the onset of this therapy and that the association with aspirin should be careful.
authors.affiliation: Service de Médecine interne et de Thérapeutique, Hôpital Sainte-Marguerite, Marseille. pambrosi@mail.ap-hm.fr
authors.forename: P
authors.initials: P
authors.lastname: Ambrosi
authors.forename: G
authors.initials: G
authors.lastname: Calise
authors.forename: P
authors.initials: P
authors.lastname: Villani
authors.forename: R
authors.initials: R
authors.lastname: Luccioni
authors.forename: G
authors.initials: G
authors.lastname: Bouvenot
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011307:Drug Prescriptions; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011446:Prospective Studies; D012307:Risk Factors; D011795:Surveys and Questionnaires; D013923:Thromboembolism / Q000517:prevention & control*; D013997:Time Factors; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight